MDMatthew R. Dunn

Matthew R. Dunn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew R. Dunn has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparing Outcomes: In-Person and Telehealth Oncology Visits

    by Ilona Fridman, Christine Neslund-Dudas, Lauren Jordan Barrow, Matthew R. Dunn, Regina Jones, Alan C. Kinlaw, Angela B. Smith, Jacob N. Stein, Samantha Tam, William A. Wood, et al.

    PURPOSE: Telemedicine offers significant benefits, but concerns regarding care quality persist. To inform future oncology telehealth policy, we compared subsequent health care use, patient-reported care quality, and communication outcomes between telehealth and in-person visits. METHODS: An observational cohort study (April 2022-October 2023) included patients age 21+ years with malignant neoplasms, a scheduled oncology visit, and cancer treatment initiated 6 months to 3 years before the study. Black adults and those with telehealth visits were oversampled. Pre- and post-visit telephone survey data were joined with electronic health record data and geocoded community characteristics. Outcomes included subsequent acute care events (emergency department visits and unplanned hospitalizations), follow-up visits, patient perceptions of whether their care needs were met, and communication quality via validated instruments, with Likert-scale responses. We estimated prevalence differences (PDs) in outcomes by visit type using propensity score–weighted generalized linear models that adjusted for patient socioeconomic, health, and census tract–level differences. RESULTS: After propensity score adjustments achieved covariate balance, 487 respondents (93 telehealth, 394 in-person) were included. Mean age was 64 (standard deviation = 13) years; 62% were female, 26% were Black, 82% had some college degree or more, and 25% reported fair/poor health. Follow-up in-person visits at 30 days were more frequent after telehealth (64%, 46%; PD = 0.18 [95% CI, 0.07 to 0.28]), with no differences at 7 or 14 days. Acute care use did not significantly differ at any time point. Quality and communication ratings were similar (PD range: 0.00-0.09), except for perceived privacy: 80% in-person, 67% telehealth, P < .01. CONCLUSION: Although mostly similar health care use and patient perceptions suggest telehealth as a viable oncology option, identified differences highlight the need to ensure privacy and evaluate when telehealth visits are most appropriate.


  • Open Access

    Comparing Neighborhood Indices of Socioeconomic Status, Segregation, and Healthcare Access for Predicting Late-Stage Breast Cancer

    by Matthew R. Dunn, Srijon Mukhopadhyay, Scarlett L. Gomez, Lauren E. McCullough, Terry Hyslop, Marc A. Emerson, Melissa A. Troester

    Composite indices of neighborhood-level social environment are frequently used in cancer research, but relationships among these indices have been seldom studied, especially in race-stratified analyses. We considered four census tract-level social indices: Neighborhood Deprivation Index (NDI; continuous, quartiles, and clusters); Yost (continuous, quartiles, and clusters); racialized-income Index of Concentration at the Extremes (ICE; continuous, quartiles, and clusters); and a care access metric (categorical). These were linked to the Carolina Breast Cancer Study, a cohort of 2998 adults (50% Black, 50% aged < 50 years) with invasive breast cancer, diagnosed 2008–2013 in North Carolina, USA. Age-adjusted associations of each index with late-stage breast cancer (stage III–IV) were assessed using generalized linear models and relative frequency differences (RFDs) and 95% confidence intervals (CIs). There were strong correlations (> 0.79 for pairwise comparisons) between the continuous NDI, Yost, and ICE, but pairwise agreement was moderate (55% to 70%) among indices as quartiles. Care access had low concordance with the other three indices. Among Black participants, late-stage breast cancer was associated with all indices, including the most disadvantaged quartile (vs least) of NDI (RFD = 7.0%, 95% CI: 1.6, 12.4), Yost (RFD = 8.8%, 95% CI: 3.3, 14.3), and ICE (RFD = 7.6%, 95% CI: 2.2, 13.0) and was strongly associated with care access (RFD = 9.4%, 95% CI: 3.8, 15.0). These associations were not significant among non-Black participants. Overall, multiple neighborhood-level social indices, including one based on healthcare data, are associated with late-stage breast cancer among Black participants, suggesting multiple dimensions of vulnerability to structural barriers.

  • The relationship between impaired upper-body function, quality of life and breast cancer-related lymphoedema: results from a prospective, population-based cohort study

    by Hildegard M. Reul-Hirche, Matthew R. Dunn, Melanie L. Plinsinga, E.-Liisa Laakso, Melissa A. Troester, Sandra C. Hayes

    Purpose To describe upper-body function in women after breast cancer treatment; and to explore the relationship between upper-body function, quality of life and breast cancer- related lymphoedema up to 7-years post-diagnosis. Methods This study uses data collected in a prospective, longitudinal, population-based, breast cancer cohort study. The Disability of Arm, Shoulder and Hand questionnaire (short version -QuickDASH), the Functional Assessment of Cancer Therapy-Breast questionnaire (FACT-B) and self-report of a clinical diagnosis were used to assess upper-body function, quality of life and breast cancer-related lymphoedema, respectively, in 2,876 women with invasive breast cancer at three time points: baseline (up to 9 months post-diagnosis), and at 2- and 7-years post-diagnosis. Unadjusted cross-sectional relationships between outcomes of interest were tested at each time point. Unadjusted and adjusted regression analyses were used to explore the potential predictive relationship between upper-body function and lymphoedema. Results Upper-body impairment was common up to 7-years post-diagnosis with > 60% of women reporting at least mild impairment and 23.8–25.6% reporting moderate to very severe impairment. Impaired upper-body function at baseline assessment was associated with poorer overall quality of life (mean (standard deviation) FACT-B for no versus mild impairment: 77.5 (11.8) versus 70.9 (12.1), p < 0.05) and increased odds of breast cancer-related lymphoedema at 2 and 7 years follow-up (moderate to severe upper-body function impairment at 2- and 7- years post-diagnosis: Odds Ratio (95% Confidence interval) 2.49 (1.57, 3.93) and 2.54 (1.51, 4.26), respectively). Conclusion Future research evaluating whether prospective monitoring of upper-body function and interventions that can address impairment can reduce the risk of breast cancer-related lymphoedema are warranted.


  • Open Access

    Tumor biology and access to care and metastatic breast cancer outcomes

    by Matthew R. Dunn, Sarah C. Van Alsten, Marc A. Emerson, Katherine Reeder-Hayes, Terry Hyslop, Melissa A. Troester

    Purpose: To understand how access to care influences metastatic breast cancer burden (MBC) while accounting for molecular tumor characteristics, and identify interventions to reduce metastatic disease burden. Methods: The Carolina Breast Cancer Study is a population-based cohort with invasive breast cancer (diagnosed 2008–2013). Both de novo metastasis (stage IV at diagnosis) and distant recurrence were evaluated (12 years of follow-up. Tumor data were from medical records, pathology reports, and RNA expression data. Social variables and access to care were from participant surveys. Generalized linear models were used to estimate associations of biological and access characteristics with MBC; Cox models were used to estimate recurrence hazards. Results: 464/2998 patients (15.5%) had MBC (n = 109 de novo ; n = 355 recurrent). MBC was associated with grade 3 vs 1 (odds ratio (OR) = 4.15, 95% CI: 2.60, 6.99), LumB vs LumA (OR = 2.08, 95% CI: 1.48, 2.90), and high vs low PAM50 risk of recurrence score (OR = 4.45, 95% CI: 2.93, 6.99) vs. non-MBC. MBC was associated with Black race (Hazard ratio (HR) = 1.66, 95% CI: 1.32, 2.11), poverty (HR = 1.47; 95% CI: 1.09, 1.99), and low education (HR = 1.48, 95% CI: 1.03, 2.13). Controlling for healthcare access (screening, regular care, delayed treatment, and community healthcare) attenuated associations with metastasis for poverty and education, but had lesser effects on race associations. Conclusions: Disparities in MBC burden persist after adjustment for individual- and community-level healthcare access. Reducing burden of MBC in Black women necessitates simultaneous targeting of biological and access to care factors.


  • Open Access

    Supplemental Table 3 from Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness

    by Matthew R. Dunn, Hongqian Niu, Didong Li, Marc A. Emerson, Caroline A. Thompson, Hazel B. Nichols, Mya L. Roberson, Stephanie B. Wheeler, Terry Hyslop, Jennifer Elston Lafata, et al.

    Supplemental Table 3: Alternate models are shown for delayed and prolonged treatment with stratification (rather than adjustment, as in the main analysis) for patients with stage I, II, or III-IV breast cancer.

  • Open Access

    Supplemental Table 2 from Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness

    by Matthew R. Dunn, Hongqian Niu, Didong Li, Marc A. Emerson, Caroline A. Thompson, Hazel B. Nichols, Mya L. Roberson, Stephanie B. Wheeler, Terry Hyslop, Jennifer Elston Lafata, et al.

    Supplemental Table 2: Summary of statistical fit criteria (including AIC, BIC, SABIC, entropy, and sample size) used to evaluate optimal number of latent class groups

  • Open Access

    Data from Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness

    by Matthew R. Dunn, Hongqian Niu, Didong Li, Marc A. Emerson, Caroline A. Thompson, Hazel B. Nichols, Mya L. Roberson, Stephanie B. Wheeler, Terry Hyslop, Jennifer Elston Lafata, et al.

    Background:Geographic disparities in breast cancer outcomes exist. Few studies have examined community- and health system–level factors associated with care timeliness, an important measure of care quality.Methods:The Carolina Breast Cancer Study is a population-based cohort of 2,998 women with invasive breast cancer (2008–2013). Using latent class modeling, patients’ census tracts of residence were characterized by healthcare accessibility and affordability. Centers for Medicare and Medicaid Services ratings were used to classify hospitals as low- or high-quality. Six timeliness outcomes were assessed: (i) lacking prediagnostic regular care, (ii) being underscreened, (iii) late-stage diagnosis, (iv) delayed treatment initiation, (v) prolonged treatment duration, and (vi) lacking receipt of Oncotype DX genomic testing. Associations of geographic accessibility, healthcare affordability, and hospital-level quality with care timeliness were evaluated with relative frequency differences (RFD) and 95% confidence intervals (CI).Results:Compared with “high-accessibility, high-affordability” census tracts, patients residing in “low-accessibility, low-affordability” areas were more likely to be underscreened (RFD = 18.7%, CI, 13.0, 24.3), have late-stage diagnosis (RFD = 6.2%, CI, 2.4, 10.1), and experience prolonged treatment (RFD = 6.9%, CI, 1.4, 12.3). “High-accessibility, low-affordability” areas had the highest frequency of treatment delay (RFD = 9.3%, CI, 3.9, 14.7). Initial surgery at a high-quality facility was associated with less delayed treatment (RFD = −3.9%, CI, −7.5, −0.4) and prolonged treatment (RFD = −5.9%, CI, −9.9, −1.9).Conclusions:Community- and health system–level factors were associated with timely breast cancer care.Impact:Policy efforts to improve access in communities should consider multiple dimensions of access, including geospatial accessibility and affordability.

  • Open Access

    Supplemental Table 1 from Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness

    by Matthew R. Dunn, Hongqian Niu, Didong Li, Marc A. Emerson, Caroline A. Thompson, Hazel B. Nichols, Mya L. Roberson, Stephanie B. Wheeler, Terry Hyslop, Jennifer Elston Lafata, et al.

    Supplemental Table 1: Description of care outcomes evaluated in this study, spanning pre-diagnostic (2x), diagnostic (1x), and post-diagnostic (3x) care.

  • Open Access

    Supplemental Figure 1 from Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness

    by Matthew R. Dunn, Hongqian Niu, Didong Li, Marc A. Emerson, Caroline A. Thompson, Hazel B. Nichols, Mya L. Roberson, Stephanie B. Wheeler, Terry Hyslop, Jennifer Elston Lafata, et al.

    Supplemental Figure 1: Cell values are predicted means for variables (normalized by square root transformation) used in the latent class model. Predicted means are conditional given classification into a latent class group (listed along the top row). Reading across a row, a cell with a relatively high value (compared to others in the row) indicates higher frequency of the given characteristic in that latent class group compared to other latent class groups. Ns correspond to the number of North Carolina census tracts in each group.

  • Open Access

    Physical Activity Patterns According to Demographic, Social, and Clinical Correlates Among Breast Cancer Survivors

    by Michael A. Kebede, Charles E. Matthews, Matthew R. Dunn, Natasha R. Burse, Annie G. Howard, Kelly R. Evenson, Melissa A. Troester

    Introduction: Moderate to vigorous physical activity (MVPA) after breast cancer diagnosis is associated with improved survivorship. However, differences in MVPA by race among breast cancer survivors are not well described in population‐based studies.Methods: We analyzed data from Carolina Breast Cancer Study Phase 3 (n = 2994, 50% Black) participants to evaluate the trajectory of MVPA from pre‐diagnosis to 18‐month post‐diagnosis. Participants self‐reported MVPA at baseline (pre‐diagnosis) and 6‐ and 18‐month post‐diagnosis and were classified as having any MVPA (> 0 min/week) or no MVPA. Associations between MVPA and demographic, social, and clinical variables were estimated using multivariable logistic regression.Results: At baseline, 84.0% of participants reported any MVPA pre‐diagnosis, which dropped to 55.4% at 6‐month post‐diagnosis, then rebounded to 85.1% by 18‐month post‐diagnosis. Among those who had no MVPA pre‐diagnosis, 32.5% and 71.0% became active at 6‐ and 18‐month post‐diagnosis, respectively. Higher income [adjusted odds ratio (aOR) = 1.33, 95% confidence interval (CI) (1.02, 1.74) > $30K vs. < 15K], lower body mass index [aOR = 1.30, 95% CI (1.00, 1.73) < 25 vs. > 30], low area deprivation [aOR = 1.35, 95% CI (1.08, 1.67) vs. high], high area assets [aOR = 1.54, 95% CI (1.23, 1.93) vs. low], and stage I breast cancer [aOR = 1.72, 95% CI (1.22, 2.43) vs. 3 or 4] were associated with any MVPA at 18‐month post‐diagnosis.Conclusion: We identified several demographic and social correlates of any MVPA at 18‐month post‐diagnosis, and together with established clinical correlates (such as late disease), these factors may contribute to breast cancer disparities.